Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Органопротективные эффекты рамиприла в лечении артериальной гипертонии
Органопротективные эффекты рамиприла в лечении артериальной гипертонии
Леонова М.В. Органопротективные эффекты рамиприла в лечении артериальной гипертонии. Consilium Medicum. 2014; 16 (1): 7–12.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Dzau VJ, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121: 1244–63.
2. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208–19.
3. Ceconi C, Francolini G, Olivares A et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007; 577: 1–6.
4. Todd PA, Benfield P. Ramipril: а review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990; 39 (1): 110–35.
5. Comini L, Bachetti T, Cargnoni A et al. Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharm Res 2007; 56: 42–8.
6. Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115 (1): 41–6.
7. Agabati-Rosei E, Ambriosoni E, Dal Palu C et al. RACE Study Group. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension: results of the RACE (ramipril cardioprotective evaluation) study. J Hypertens 1995; 13: 1325–34.
8. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821–8.
9. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997; 349: 1493–7.
10. Willenheimer R, Juul-Möller S, Forslund L, Erhardt L. No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months. Curr Control Trials Cardiovasc Med 2001; 2 (2): 99–105.
11. Lonn EM, Yusuf S, Doris CI et al. Effects of ramipril and vitamin E on atherosclerosis. Circulation 2001; 103: 919–25.
12. The GISEN Group. Randomised placebo-controlled trail of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nefropathy. Lancet 1997; 349: 1857–63.
13. Wright JT, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421–31.
14. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–9.
15. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547–53.
16. Coca A. Cerebral involvement in hypertensive cardiovascular disease. Eur Heart J 2003; 5 (Suppl. F): F19–25.
17. Regenhardt RW. Understanding the Cerebroprotective Actions of the Ace2/Ang-(1-7)/Mas Axis during Ischemic and Hemorrhagic Stroke. ETDs 2012.
18. Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 1–5.
19. The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 2008; 358: 1547–59.
20. Ellul J, Archer N, Foy CML et al. The effects of commonly prescribed drugs in patients with Alzheimer’s disease on the rate of deterioration. J Neurol Neurosurg Psychiatry 2007; 78: 233–9.
21. Dong Y-F, Kataoka K, Tokutomi Y et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB J 2011; 25: 2911–20.
22. Ohrui T, Tomita N, Sato-Nakagawa et al. Effects of brainpenetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324–5.
23. Qureshi N, Babbar R. Effect of ramipril therapy on cognitive functions in cases of mild to moderate essential hypertension. Indian J Physiol Pharmacol 2007; 51 (1): 40–8.
24. Anderson C, Teo K, Gao P et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurology 2011; 10 (1): 43–53.
25. The DREAM Trial Investigators. Effect of Ramipril on the Incidence of Diabetes. N Engl J Med 2006; 355: 1551–62.
26. Zidek W, Schrader J, Lüders S et al. Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study. Cardiovasc Diabetology 2012; 11: 1–11.
27. Марцевич С.Ю., Лукина Ю.В., Дмитриева Н.А. и др. Сравнительное исследование нового дженерического препарата рамиприла с оригинальным препаратом у больных артериальной гипертонией и высоким риском развития сердечно-сосудистых осложнений. В кн.: Основы доказательной медицины. 2010.
28. Колос И.П., Мартынюк T.B., Сафарян А.С. и др. Изучение эффективности терапии ингибитором ангиотензинпревращающего фермента рамиприлом и его комбинации с гидрохлоротиазидом у пациентов с артериальной гипертонией и избыточной массой тела: исследование ХАРИЗМА. Кардиоваск. терапия и профилактика. 2008; 2 (4): 65–71.
29. Чазова И.Е., Мартынюк T.B., Небиеридзе Д.В. и др. Сравнительная эффективность лечения фиксированными комбинациями различных доз рамиприла и гидрохлоротиазида. Кардиоваск. терапия и профилактика. 2010; 9 (4): 25–31.
2. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208–19.
3. Ceconi C, Francolini G, Olivares A et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007; 577: 1–6.
4. Todd PA, Benfield P. Ramipril: а review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990; 39 (1): 110–35.
5. Comini L, Bachetti T, Cargnoni A et al. Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharm Res 2007; 56: 42–8.
6. Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115 (1): 41–6.
7. Agabati-Rosei E, Ambriosoni E, Dal Palu C et al. RACE Study Group. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension: results of the RACE (ramipril cardioprotective evaluation) study. J Hypertens 1995; 13: 1325–34.
8. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821–8.
9. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997; 349: 1493–7.
10. Willenheimer R, Juul-Möller S, Forslund L, Erhardt L. No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months. Curr Control Trials Cardiovasc Med 2001; 2 (2): 99–105.
11. Lonn EM, Yusuf S, Doris CI et al. Effects of ramipril and vitamin E on atherosclerosis. Circulation 2001; 103: 919–25.
12. The GISEN Group. Randomised placebo-controlled trail of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nefropathy. Lancet 1997; 349: 1857–63.
13. Wright JT, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421–31.
14. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–9.
15. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547–53.
16. Coca A. Cerebral involvement in hypertensive cardiovascular disease. Eur Heart J 2003; 5 (Suppl. F): F19–25.
17. Regenhardt RW. Understanding the Cerebroprotective Actions of the Ace2/Ang-(1-7)/Mas Axis during Ischemic and Hemorrhagic Stroke. ETDs 2012.
18. Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 1–5.
19. The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 2008; 358: 1547–59.
20. Ellul J, Archer N, Foy CML et al. The effects of commonly prescribed drugs in patients with Alzheimer’s disease on the rate of deterioration. J Neurol Neurosurg Psychiatry 2007; 78: 233–9.
21. Dong Y-F, Kataoka K, Tokutomi Y et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB J 2011; 25: 2911–20.
22. Ohrui T, Tomita N, Sato-Nakagawa et al. Effects of brainpenetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324–5.
23. Qureshi N, Babbar R. Effect of ramipril therapy on cognitive functions in cases of mild to moderate essential hypertension. Indian J Physiol Pharmacol 2007; 51 (1): 40–8.
24. Anderson C, Teo K, Gao P et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurology 2011; 10 (1): 43–53.
25. The DREAM Trial Investigators. Effect of Ramipril on the Incidence of Diabetes. N Engl J Med 2006; 355: 1551–62.
26. Zidek W, Schrader J, Lüders S et al. Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study. Cardiovasc Diabetology 2012; 11: 1–11.
27. Марцевич С.Ю., Лукина Ю.В., Дмитриева Н.А. и др. Сравнительное исследование нового дженерического препарата рамиприла с оригинальным препаратом у больных артериальной гипертонией и высоким риском развития сердечно-сосудистых осложнений. В кн.: Основы доказательной медицины. 2010.
28. Колос И.П., Мартынюк T.B., Сафарян А.С. и др. Изучение эффективности терапии ингибитором ангиотензинпревращающего фермента рамиприлом и его комбинации с гидрохлоротиазидом у пациентов с артериальной гипертонией и избыточной массой тела: исследование ХАРИЗМА. Кардиоваск. терапия и профилактика. 2008; 2 (4): 65–71.
29. Чазова И.Е., Мартынюк T.B., Небиеридзе Д.В. и др. Сравнительная эффективность лечения фиксированными комбинациями различных доз рамиприла и гидрохлоротиазида. Кардиоваск. терапия и профилактика. 2010; 9 (4): 25–31.
Авторы
М.В.Леонова
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России, Москва
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.